At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 33 enrolled
Drug / intervention
RAD001drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia
In Brief
A Phase 2 clinical trial evaluating RAD001 for Waldenstrom's Macroglobulinemia. Completed, enrolled 33 participants across 1 site.
Detailed Summary
The purpose of this research study is to determine the safety of RAD001(Everolimus) and the highest dose of this drug that can be given to people safely. RAD001(Everolimus) is a drug that works by preventing cells in the body from growing and dividing. Information from basic and Phase I clinical research studies suggests that RAD001 also may help to prevent tumor growth in people with relapsed or refractory lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWaldenstrom's Macroglobulinemia
CountriesUnited States
CollaboratorsBrigham and Women's Hospital, Novartis
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2009
Enrollment StartNov 2009
Primary CompletionJul 2016
Study CompletionJul 2018
TodayJul 2026
First PostedSep 14, 2009
Enrollment StartNov 1, 2009
Primary CompletionJul 1, 2016
Study CompletionJul 1, 2018
TodayJul 2, 2026
Enrollment to primary: 6.7 yearsPosted 16.8 years ago
Interventions
RAD001drug
Taken orally once a day